Clinical trials in the Commonwealth of the Independent States

The Commonwealth of the Independent States (CIS) is a union of post-Soviet countries, which aims to maintain economic benefits established between the former members of the USSR, while they were a single state. The CIS include Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, and Uzbekistan. Smooth Drug Development offers clinical trials services in the CIS.

Having been a part of the Soviet centralised healthcare system, the CIS member states established their clinical trial infrastructure around gigantic medical institutions, which were lavishly sponsored during the Soviet reign and facilitated development of clinical trial sites after the collapse of the USSR. While the CIS countries maintain good clinical trial infrastructure, their economies are fluctuating. This keeps clinical trials expenses low and help to safe up to 60% of clinical trial budget. Yet another specificity of the region is widespread state-sponsored medical education, in the result of which many of CRO staff hold MD degrees.

Smooth Drug Development helps Sponsors to utilize unique advantages of the CIS countries and offer full-cycle clinical trials services, guided by the highest quality standards. Smooth Drug Development is dedicated to quality control and holds ISO 9001:2015 certificate in “Quality Management System.” The Smooth QMS reaches out to each and every aspect of our activity. Hence, Smooth Drug Development guarantees strict control over the clinical trials in the CIS countries.

Smooth Drug Development makes research in the CIS fast and cost-effective and guarantees the highest quality.